Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1655-1657

  Trancart, Stéphanie ^a   Charreau, Isabelle ^b   Marchou, Bruno ^a   Bocquentin, Muriel ^c   Molina, Jean Michel ^d   Izopet, Jacques ^a   Tangre, Philippe ^b   Aboulker, Jean Pierre ^b   Taburet, Anne Marie ^c   Ragnaud, J M ^e   Beylot, J ^e   Morlat, P ^e   Dupon, M ^e   Breilh, D ^e   Lagarde, P ^f   David Ouaknin, F ^f   Raffi, F ^g   Dailly, E ^g   Girard, P M ^h   Meynard, J L ^h   Poirier, J M ^h   Molina, J M ^h   Sauvageon, H ^h   Massip, P ⁱ   Marchou, B ⁱ   Lavit, M ⁱ   Stahl, J P ^j   Leclercq, P ^j   Stanke, F ^j   Touraine, J L ^k   Livrozet, J M ^k   Gagneux, M C ^k   Rey, E ^l   more..

^a CHU PURPAN   (France)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f Centre hospitalier de Lagny Marne la Vallee   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k HOSPICES CIVILS DE LYON   (France)

^l NONE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HALF-LIFE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84857180088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05452-11     Document Type: Article

References (23)

1. Bazzoli C, et al. 2011. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob. Agents Chemother. 55:3423-3431.
2. Chaix ML, et al. 2006. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus Abidjan, Cote d'Ivoire. J. Infect. Dis. 193:482-487.
3. Chi BH, et al. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705. (Pubitemid 350100773)
4. di Iulio J, et al. 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19:300-309.
5. Haas DW, et al. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400. (Pubitemid 40065906)
6. Haas DW, et al. 2009. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 199:872-880.
7. Hance AJ, et al. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417. (Pubitemid 32578160)
8. Izopet J, et al. 2002. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis. 185:1506-1510. (Pubitemid 34507975)
9. Izopet J, et al. 2008. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response. Antivir. Ther. 13:537-545. (Pubitemid 352016716)
10. Leger P, et al. 2009. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J. Infect. Dis. 200:955-964.
11. Marchou B, et al. 2007. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 21:457-466.
12. Marzolini C, et al. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. (Pubitemid 32055781)
13. McIntyre JA, et al. 2009. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 6:e1000172.
14. Mehlotra RK, Bockarie MJ, Zimmerman PA. 2007. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. 64:391-395. (Pubitemid 47283857)
15. Metzner KJ, et al. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188:1433-1443. (Pubitemid 37523928)
16. Mo SL, et al. 2009. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 10:730-753.
17. Mukonzo JK, et al. 2009. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68:690-699.
18. Palmer S, et al. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413. (Pubitemid 40096331)
19. Pirillo M, et al. 2010. Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial. AIDS Res. Hum. Retroviruses 26:541-545.
20. Powers V, Ward J, Gompels M. 2009. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV Med. 10:520-523.
21. Ribaudo HJ, et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42:401-407. (Pubitemid 43122320)
22. Taylor S, Boffito M, Khoo S, Smit E, Back D. 2007. Stopping antiretroviral therapy. AIDS 21:1673-1682. (Pubitemid 47237553)
23. Wang J, et al. 2006. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16:191-198.